Arca
Skip to content

Bimatoprost

ANDA 210515, held by Alembic. Bimatoprost.

  • First approved: Jan 21, 2020
  • Review: Standard
  • Supplements approved: 2
  • Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 3 submissions below
DateSubmissionStatusDocuments
Jan 21, 2020Original applicationApprovedNone posted

Products

1 strengths and forms
ProductActive ingredientMarketing
Bimatoprost0.03% · solution/drops;topicalBimatoprostRx
All 3 submissions, including labeling and manufacturing supplements
DateSubmissionStatusDocuments
Nov 28, 2023Supplement 2Labeling · Standard reviewApprovedNone posted
Nov 28, 2023Supplement 3Labeling · Standard reviewApprovedNone posted
Jan 21, 2020Original applicationApprovedNone posted

Identifiers

Application
ANDA 210515

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed weekly; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.